LY3884963

Phase 2Biologic

Eli Lilly

LY3884963 is one of 12 biologic programs targeting Frontotemporal Dementia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Frontotemporal DementiaActive, not recruiting

Frontotemporal DementiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Frontotemporal Dementia

#DrugCompanyPhaseTrials

Namenda

AbbVie

Approved

1 2

Celexa

AbbVie

Approved

1 3

Gocovri

GGrupo Espanol de Tumores Neuroendocrinos

Approved

1 4

Rapamune

PPrism Pharmaceuticals

Glucophage

Rayos

Brintellix

1 8

Medrol

Pfizer

Phase 1

1 9

NS101

NNeuracle Science Co., LTD.

Phase 2

1 10

LY3884963

Eli Lilly

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

PreclinicalActive, not recruiting

Frontotemporal Dementia

NCT04408625

Clinical

Trials by Indication[1]

Frontotemporal Dementia1 trial

A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Preclinical·NCT04408625·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LY3884963. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY3884963 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY3884963. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

LY3884963

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Frontotemporal Dementia1 trial

References

Drug Info

Quick Facts

Related News